Adamis Pharmaceuticals (NASDAQ:ADMP) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is unchanged from the same period last year.
Raymond James Maintains Outperform on Sunoco, Raises Price Target to $51
Raymond James analyst Justin Jenkins maintains Sunoco (NYSE:SUN) with a Outperform and raises the price target from $50 to $51.
